Free Delivery on orders over £29*

Simparica Flea & Tick Tablets

Simparica Flea & Tick Tablets
5mg » Pack of 3 Chewable Tablets

  • 5mg » Pack of 3 Chewable Tablets £16.49
  • 10mg » Pack of 3 Chewable Tablets £17.50
  • 20mg » Pack of 3 Chewable Tablets £19.49
  • 40mg » Pack of 3 Chewable Tablets £20.50
  • 80mg » Pack of 3 Chewable Tablets £23.50
  • 120mg » Pack of 3 Chewable Tablets £31.99

Selection of 6 products from

£16.49 to £31.99

Description

This product is sourced in the United Kingdom and is intended for use in the United Kindgom only.

Simparica™ (sarolaner) Chewables are safe, monthly flea and tick protection for dogs that start working fast and remain effective all month long.

Simparica™ starts killing fleas within 3 hours and ticks within 8 hours, and it keeps going strong for 35 days without losing effectiveness at the end of the month.

Proven persistent protection against fleas and ticks.

Simparica is effective against fleas and ticks, even on day 35! You can count on Simparica to do the following:

  • Provide rapid relief for pets with existing flea infestations, even dogs with flea allergies
  • Improve clinical signs of flea allergies in dogs by eliminating fleas
  • Prevent and control home flea infestations, killing fleas before they can lay eggs
  • Quickly kill ticks, which may help reduce the risk of potentially life-threatening flea- and tick-borne diseases

Presentation

Simparica chewable tablets are brown, square tablets with 5, 10, 20, 40 or 80 embossed on one side. Each tablet contains:

Simparica chewable tablets sarolaner (mg)
for dogs 1.3 - 2.5 kg 5
for dogs >2.5 - 5 kg 10
for dogs >5 - 10 kg 20
for dogs >10 - 20 kg 40
for dogs >20 - 40 kg 80
for dogs >40 - 60 kg 120

Uses

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis) in dogs. Simparica has immediate and persistent flea killing activity against new infestations for at least 5 weeks. Simparica can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). Simparica has immediate and persistent tick killing activity for at least 5 weeks. For the treatment of sarcoptic mange (Sarcoptes scabiei). Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Dosage and administration

For oral use. Tablets can be administered with or without food. Simparica should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:

Bodyweight (kg) Tablet strength (mg sarolaner) Number of tablets to be administered
1.3 - 2.5 5 One
>2.5 - 5 10 One
>5 - 10 20 One
>10 - 20 40 One
>20 - 40 80 One
>40 - 60 120 One
>60 Appropriate combination of tablets

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg. Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided. Treatment schedule: For optimal control of flea and tick infestations, Simparica should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations. For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded. In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian. The safety of Simparica has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian. Simparica has been administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum dose and convulsions at 5 times the maximum dose. All dogs recovered without treatment. Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed. User warnings Wash hands after handling the product. The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pharmaceutical precautions

Simparica does not require any special storage conditions. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Keep out of the sight and reach of children. For animal treatment only.

Legal Category

POM-V

Further information

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines. For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours. Simparica kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access. In addition, in laboratory studies, sarolaner was shown to be active against other tick species such as Dermacentor variabilis, Ixodes scapularis, Amblyomma americanum, Amblyomma maculatum as well as the mite species Demodex canis and Otodectes cynotis. During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed. In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated). Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

Marketing Authorisation Number

EU/2/15/191/001-018

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

10mg » Pack of 3 Chewable Tablets

Simparica chewable tablets for dogs

Presentation

Simparica chewable tablets are brown, square tablets with 5, 10, 20, 40, 80 or 120 embossed on one side. Each tablet contains:

Simparica chewable tablets sarolaner (mg)
for dogs 1.3 - 2.5 kg 5
for dogs >2.5 - 5 kg 10
for dogs >5 - 10 kg 20
for dogs >10 - 20 kg 40
for dogs >20 - 40 kg 80
for dogs >40 - 60 kg 120

Uses

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis) in dogs. Simparica has immediate and persistent flea killing activity against new infestations for at least 5 weeks. Simparica can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). Simparica has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (Demodex canis).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Dosage and administration

For oral use.

Tablets can be administered with or without food. Simparica should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.

Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.

Treatment schedule:

For optimal control of flea and tick infestations, Simparica should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

For the treatment of ear mite infestations (Otodectes cynotis) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by Demodex canis) the administration of a single dose once a month for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) adverse reactions associated with mild and transient gastrointestinal effects such as vomiting and diarrhoea may occur. In very rare cases transient neurological disorders such as tremor, ataxia or convulsion may occur. These signs typically resolve without treatment.

The safety of Simparica has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian.

Simparica has been administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum dose and convulsions at 5 times the maximum dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

User warnings

Wash hands after handling the product. The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pharmaceutical precautions

Simparica does not require any special storage conditions.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in cartons containing 1, 3 or 6 tablets. Not all pack sizes may be marketed.

Further information

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours.

Simparica kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.

During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).

Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

Marketing Authorisation Number

EU/2/15/191/001-018

20mg » Pack of 3 Chewable Tablets

Simparica chewable tablets for dogs

Presentation

Simparica chewable tablets are brown, square tablets with 5, 10, 20, 40, 80 or 120 embossed on one side. Each tablet contains:

Simparica chewable tablets sarolaner (mg)
for dogs 1.3 - 2.5 kg 5
for dogs >2.5 - 5 kg 10
for dogs >5 - 10 kg 20
for dogs >10 - 20 kg 40
for dogs >20 - 40 kg 80
for dogs >40 - 60 kg 120

Uses

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis) in dogs. Simparica has immediate and persistent flea killing activity against new infestations for at least 5 weeks. Simparica can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). Simparica has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (Demodex canis).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Dosage and administration

For oral use.

Tablets can be administered with or without food. Simparica should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.

Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.

Treatment schedule:

For optimal control of flea and tick infestations, Simparica should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

For the treatment of ear mite infestations (Otodectes cynotis) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by Demodex canis) the administration of a single dose once a month for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) adverse reactions associated with mild and transient gastrointestinal effects such as vomiting and diarrhoea may occur. In very rare cases transient neurological disorders such as tremor, ataxia or convulsion may occur. These signs typically resolve without treatment.

The safety of Simparica has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian.

Simparica has been administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum dose and convulsions at 5 times the maximum dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

User warnings

Wash hands after handling the product. The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pharmaceutical precautions

Simparica does not require any special storage conditions.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in cartons containing 1, 3 or 6 tablets. Not all pack sizes may be marketed.

Further information

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours.

Simparica kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.

During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).

Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

Marketing Authorisation Number

EU/2/15/191/001-018

40mg » Pack of 3 Chewable Tablets

Simparica chewable tablets for dogs

Presentation

Simparica chewable tablets are brown, square tablets with 5, 10, 20, 40, 80 or 120 embossed on one side. Each tablet contains:

Simparica chewable tablets sarolaner (mg)
for dogs 1.3 - 2.5 kg 5
for dogs >2.5 - 5 kg 10
for dogs >5 - 10 kg 20
for dogs >10 - 20 kg 40
for dogs >20 - 40 kg 80
for dogs >40 - 60 kg 120

Uses

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis) in dogs. Simparica has immediate and persistent flea killing activity against new infestations for at least 5 weeks. Simparica can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). Simparica has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (Demodex canis).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Dosage and administration

For oral use.

Tablets can be administered with or without food. Simparica should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.

Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.

Treatment schedule:

For optimal control of flea and tick infestations, Simparica should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

For the treatment of ear mite infestations (Otodectes cynotis) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by Demodex canis) the administration of a single dose once a month for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) adverse reactions associated with mild and transient gastrointestinal effects such as vomiting and diarrhoea may occur. In very rare cases transient neurological disorders such as tremor, ataxia or convulsion may occur. These signs typically resolve without treatment.

The safety of Simparica has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian.

Simparica has been administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum dose and convulsions at 5 times the maximum dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

User warnings

Wash hands after handling the product. The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pharmaceutical precautions

Simparica does not require any special storage conditions.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in cartons containing 1, 3 or 6 tablets. Not all pack sizes may be marketed.

Further information

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours.

Simparica kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.

During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).

Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

Marketing Authorisation Number

EU/2/15/191/001-018

80mg » Pack of 3 Chewable Tablets

Simparica chewable tablets for dogs

Presentation

Simparica chewable tablets are brown, square tablets with 5, 10, 20, 40, 80 or 120 embossed on one side. Each tablet contains:

Simparica chewable tablets sarolaner (mg)
for dogs 1.3 - 2.5 kg 5
for dogs >2.5 - 5 kg 10
for dogs >5 - 10 kg 20
for dogs >10 - 20 kg 40
for dogs >20 - 40 kg 80
for dogs >40 - 60 kg 120

Uses

For the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis) in dogs. Simparica has immediate and persistent flea killing activity against new infestations for at least 5 weeks. Simparica can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD).

For the treatment of tick infestations (Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus). Simparica has immediate and persistent tick killing activity for at least 5 weeks.

For the treatment of sarcoptic mange (Sarcoptes scabiei).

For the treatment of ear mite infestations (Otodectes cynotis).

For the treatment of demodicosis (Demodex canis).

Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.

Dosage and administration

For oral use.

Tablets can be administered with or without food. Simparica should be administered at a dose of 2-4 mg/kg bodyweight in accordance with the following table:

Use appropriate combination of available strengths to achieve the recommended dose of 2–4 mg/kg.

Simparica tablets are chewable and palatable and readily consumed by dogs when offered by the owner. If the tablet is not taken up voluntarily by the dog it can also be given with food or directly into the mouth. The tablets should not be divided.

Treatment schedule:

For optimal control of flea and tick infestations, Simparica should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

For the treatment of ear mite infestations (Otodectes cynotis) a single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

For the treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) a single dose should be administered at monthly intervals for two consecutive months.

For the treatment of demodicosis (caused by Demodex canis) the administration of a single dose once a month for three consecutive months is efficacious and leads to a marked improvement of clinical signs. Treatment should be continued until skin scrapings are negative on at least two consecutive occasions one month apart. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Parasites need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious parasite-borne diseases cannot be excluded.

In the absence of available data, treatment of puppies less than 8 weeks of age and/or dogs less than 1.3 kg bodyweight should be based on a benefit-risk assessment by the responsible veterinarian.

In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports) adverse reactions associated with mild and transient gastrointestinal effects such as vomiting and diarrhoea may occur. In very rare cases transient neurological disorders such as tremor, ataxia or convulsion may occur. These signs typically resolve without treatment.

The safety of Simparica has not been established during pregnancy and lactation or in animals intended for breeding. Laboratory studies in rats and rabbits have not produced any evidence of any teratogenic effects. Use only according to the benefit/risk assessment by the responsible veterinarian.

Simparica has been administered orally to 8 week old Beagle puppies at doses of 0, 1, 3, and 5 times the maximum dose of 4 mg/kg at 28 day intervals for 10 doses. No adverse effects were observed at the maximum dose of 4 mg/kg. In the overdose groups, transient and self-limiting neurological signs were observed in some animals: mild tremors at 3 times the maximum dose and convulsions at 5 times the maximum dose. All dogs recovered without treatment.

Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose. No treatment-related clinical signs were observed.

User warnings

Wash hands after handling the product. The accidental ingestion of the product may potentially result in adverse effects, such as transient excitatory neurological signs. To prevent children from accessing the product, only one chewable tablet at a time should be removed from the blister pack and only when required. The blister pack should then be returned into the carton immediately after use and the carton should be stored out of the sight and reach of children. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.

Pharmaceutical precautions

Simparica does not require any special storage conditions.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in cartons containing 1, 3 or 6 tablets. Not all pack sizes may be marketed.

Further information

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines.

For fleas, the onset of efficacy is within 8 hours of attachment during the 28 day period after product administration. For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration. Ticks on the animal prior to administration are killed within 24 hours.

Simparica kills newly emerged fleas on the dog before they can lay eggs and therefore it prevents environmental flea contamination in areas to which the dog has access.

During clinical field trials, no interactions between Simparica chewable tablets for dogs and routinely used veterinary medicinal products were observed.

In laboratory safety studies, no interactions were observed when sarolaner was co-administered with milbemycin oxime, moxidectin and pyrantel pamoate. (In these studies efficacy was not investigated).

Sarolaner is highly bound to plasma proteins and might compete with other highly bound drugs such as non-steroidal anti-inflammatory drugs (NSAIDs) and the cumarin derivative warfarin.

Marketing Authorisation Number

EU/2/15/191/001-018

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews (2)

Q & A

Below are some recent questions we've received regarding Simparica Flea & Tick Tablets, including answers from our team.

24 September 2016 at 2:34pm

Will simparica wormer control lung worm ?

Ellen Higgins

  • VioVet customer since 2016
  • From: , United Kingdom

My vet suggested this to control demodex for my dog as he keeps having relapses even though he's been advocate so I was wondering what other medication would I need to give him to cover him for worms etc.

  • Veterinary Advisor

Between the Advocate and Simparica you are covering most internal and external parasites with the exception of tapeworms. If you continue to give Advocate alongside Simparica you could add in Droncit which is effective against tapeworm. Alternatively you could give Milbemax tablets (a mixed wormer) alongside the Simparica and be covered for everything also.